OXBR vs. NEUE, ZBAO, HUIZ, FGNX, FGF, AIFU, CNFR, TIRX, XHG, and ACGLO
Should you be buying Oxbridge Re stock or one of its competitors? The main competitors of Oxbridge Re include NeueHealth (NEUE), Zhibao Technology (ZBAO), Huize (HUIZ), Fundamental Global (FGNX), Fundamental Global (FGF), AIFU (AIFU), Conifer (CNFR), Tian Ruixiang (TIRX), XChange TEC.INC. (XHG), and Arch Capital Group (ACGLO). These companies are all part of the "insurance" industry.
Oxbridge Re vs. Its Competitors
NeueHealth (NYSE:NEUE) and Oxbridge Re (NASDAQ:OXBR) are both small-cap insurance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.
NeueHealth has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Oxbridge Re has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.
NeueHealth has a net margin of -9.08% compared to Oxbridge Re's net margin of -151.89%. NeueHealth's return on equity of 0.00% beat Oxbridge Re's return on equity.
In the previous week, Oxbridge Re had 2 more articles in the media than NeueHealth. MarketBeat recorded 3 mentions for Oxbridge Re and 1 mentions for NeueHealth. NeueHealth's average media sentiment score of 1.00 beat Oxbridge Re's score of -0.03 indicating that NeueHealth is being referred to more favorably in the media.
63.9% of NeueHealth shares are owned by institutional investors. Comparatively, 5.6% of Oxbridge Re shares are owned by institutional investors. 63.3% of NeueHealth shares are owned by insiders. Comparatively, 16.5% of Oxbridge Re shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NeueHealth presently has a consensus price target of $7.00, suggesting a potential upside of 3.40%. Oxbridge Re has a consensus price target of $5.00, suggesting a potential upside of 149.38%. Given Oxbridge Re's stronger consensus rating and higher possible upside, analysts plainly believe Oxbridge Re is more favorable than NeueHealth.
Oxbridge Re has lower revenue, but higher earnings than NeueHealth. Oxbridge Re is trading at a lower price-to-earnings ratio than NeueHealth, indicating that it is currently the more affordable of the two stocks.
Summary
NeueHealth and Oxbridge Re tied by winning 8 of the 16 factors compared between the two stocks.
Get Oxbridge Re News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OXBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxbridge Re Competitors List
Related Companies and Tools
This page (NASDAQ:OXBR) was last updated on 9/5/2025 by MarketBeat.com Staff
Free OXBR Stock Alerts